Aptar Pharma to Exhibit Innovative Drug Delivery Devices at Pharmapack 2018 in Paris, France

Image1

Aptar Pharma, a leading drug delivery systems provider, will once again be a key exhibitor at Pharmapack 2018, Europe’s dedicated pharmaceutical packaging and drug delivery event, which takes place on February 7-8 at Paris Expo, Porte de Versailles, France.

 

Aptar Pharma’s booth, located at Hall 7.1, Booth B24/B26, will present their diverse portfolio of drug delivery solutions and will showcase their latest technology innovations. A dedicated connectivity hub will center on the field of connected healthcare solutions, a significant megatrend, which can greatly improve patient behavior and adherence.

Pharmapack provides invaluable insight into the latest trends, developments and regulatory changes impacting the industry, as well as a wide variety of learning opportunities. This year, three of Aptar Pharma’s experts have been selected to share their specialist knowledge during Pharmapack.

Gerallt Williams, Director – Scientific Affairs at Aptar Pharma, will present Opportunities and Challenges of Drug Delivery Via the Nasal Route, on February 8 at 10.00 am in Conference Room 741.  Dr. Williams’ talk is part of Conference Session 3: How will New Drug Delivery Solutions Revolutionize Patient Life and Improve Treatment Adherence?

Arnaud Fournier, Senior Business Project Manager – Injectables will present a Learning Lab on February 7 at 11.30 am at Booth H2.  His talk, Setting the Standard for Film Coated Stoppers with an Unrivalled Reduction in Particulates will discuss injectable drug trends given today’s stricter regulatory requirements. With more sensitive drugs being developed, Mr. Fournier will share insight into the need for tighter quality standards and coated packaging solutions such as Aptar Pharma’s PremiumCoat™ coated stopper, which offers an unrivalled reduction in particulates.

Sai Shankar, Director Business Development – Connected Devices, will present a Learning Lab entitled Driving Better Patient Outcomes with Connectivity on February 7 at 15.50 at Booth H2. Mr. Shankar will discuss how patient behavior can be changed through connective, intuitive, user-friendly devices, which can significantly increase does adherence and improve patient health outcomes. He will also feature Aptar Pharma’s connected device portfolio which covers Application Fields such as Respiratory and Eye Care.

Aptar Pharma will also be a selected exhibitor on Pharmapack’s guided Innovation Tours on Thursday, February 8, at 10.30am at the Innovation Gallery. The Innovation Tours take visitors on a tour of highlighted exhibitors who have made innovative strides in the industry.

Visit Aptar Pharma during Pharmapack at Hall 7.1, Booth B24/B26, where their team of experts look forward to welcoming their valued customers and partners from around the world and to exchange with key opinion leaders in the industry.

With over 400 exhibitors and more than 5,000 Pharma & drug delivery professionals expected to attend Pharmapack this year, Aptar Pharma welcomes the opportunity to once again be a part of this important industry event.

Tekni-Films discusses latest in rigid and flexible packaging materials for medical device, pharma applications at MD&M West

teck

The latest in rigid and flexible packaging materials for medical device and pharmaceutical applications will be featured by Tekni-Films, a Tekni-Plex business unit, at MD&M West, February 6-8, Anaheim Convention Center, Anaheim, Calif., in Booth 2027.

Tekni-Films will be discussing its TekniMD® PX copolyester film series with grades that provide a cost effective alternative to PETG for thermoformed medical tray packaging. The company also offers a laminated alternative to PVC for thermoformed pharmaceutical blister applications.

 

Tekni-Films also will be displaying its ultra-high barrier PVDC coating and a wide variety of other multilayer packaging structures that deliver the stringent oxygen and water vapor barrier properties necessary to protect pharmaceutical and medical device products.

Doppelherz sparkles with new packaging from Sanner

sanner

In the highly competitive market for food supplements, effervescent tablets in tubes are considered one of the most effective and reliable dosage forms. In contrast to other packaging types, tubes do not crack or bend. The tablets cannot crumble; they are protected from light and moisture and have a long shelf life. The dietary supplements producer Queisser also relies on these advantages for the successful Doppelherz vitamins and minerals. Since the beginning of last year, customers receive an even more consumer-friendly and attractive packaging thanks to the Sanner Brilliance® tubes.


Holistic concept from a single source

Queisser supplies customers in Europe, Russia and Asia with effervescent tablets. The company has been using the proven and tested desiccant closures from Sanner for more than 15 years. In 2016, they decided to switch to in-mold-labeling technology to achieve higher quality printing result and, above all, an improved readability for consumers. “With the Sanner Brilliance® tubes, we offer our customers a high-end product in high-quality packaging,” says Jürgen Hennings, Product Manager Marketing at Queisser Pharma. “The brilliant printing results increase the readability of the printed information, while providing a high quality impression and more attention at point-of-sale.”
But these were not the only requirements: Queisser also needed a different tube length for the Doppelherz effervescent tablets. “Sanner was the only supplier able to promptly produce the according tube length with IML technology,” Hennings explains. Instead of the conventional 144 millimeters, the Doppelherz tubes are 165 millimeters long. Sanner developed a new IML-capable tool specifically for the production of these tubes. “The combination of flexibility, quality and trust, together with the well-known desiccant closures were determining factors for our decision,” says Hennings. The company now receives a holistic effervescent packaging solution from a single source.


Flexible packaging with brilliant design

Compared to conventional tubes printed with offset technology, IML tubes offer higher-quality, photorealistic printing with different surface structures. Up to eight colors and real metallic effects are possible. The good readability of the label, even for smaller font sizes, provides more space for product information, while the impact- and scratch-resistant decor ensures long durability.
The packaging can also be upgraded with additional features: consumers receive more detailed information via QR codes with just one click, while peel-off labels can be used as an additional information booklet. This way, customers get an attractive packaging with all the information they require in a small space – and manufacturers can increase brand loyalty thanks to a high-quality appearance and exceptional user-friendliness.

Mérieux Développement and Gimv announce the signature of an exclusivity agreement with a view to acquiring Stiplastics Healthcaring

stiplastics

Mérieux Développement and Gimv, together with the management team, announce that they have signed an exclusivity agreement with Stage Capital, Stiplastics Healthcaring’s majority shareholder, with a view to acquiring the company.

Stiplastics Healthcaring, which was founded in 1985 and has been owned by Stage Capital (formerly NBGI) since 2013, designs, develops and manufactures standard and smart plastic solutions for the pharmaceutical industries and the health sector. Based in Saint-Marcellin (Isère – France), the company currently employs over 90 people on a 10,000 m2 industrial site opened last October. The Group expects to achieve turnover of EUR 21 million in the current 2017/2018 financial year, 98% of which will be generated by the health sector. Exports account for 55% of Stiplastics’ turnover, thanks to its development of devices for the dispensing of solid-form medications (especially in the USA).

Stiplastics Healthcaring has over 30 years’ experience in medical plastics. It works with customers throughout the entire process, from formulating the exact needs until the product is launched. It is a recognised specialist in the area of treatment observance, and its range of “intelligent” pill dispensers encourage treatment observance, and make administering and taking medicines easier and safer. It has also built solid expertise in solutions for respiratory diseases. Stiplastics Healthcaring works in partnership with pharmaceutical industry leaders and has recently developed an inhalation device.

The company has a strong development potential in the connected health sector, with new products in the pipeline and a modern workshop for the production of electronic products in a controlled environment. In order to meet the new needs of patients and healthcare actors faced with changing pathologies and uses, and more specifically the increasing prominence of connected care, the Group has set up its IoC [Internet Of Care]® unit, which is dedicated to designing, developing and producing e-health medical devices. In addition, several partnership agreements were finalised in 2017 in what is an extremely promising sector, which will benefit patients and practitioners alike.

Mérieux Développement and Gimv1 have joined forces to acquire Stiplastics Healthcaring. They will contribute their complementary expertise in the health sector and support the growth of this French company. Stiplastics Healthcaring will remain under the operational management of Jérôme Empereur and Laetitia Le Gall, who have successfully developed this high-performing industrial platform, whilst creating real sales momentum in recent years.

“The Mérieux Développement – Gimv consortium is an ideal tandem that will allow Stiplastics Healthcaring to grow further and accelerate its development. They bring to the table health sector specialists as well as substantial financial resources, which is perfectly suited to support the
Group’s growth challenges” explained Jérôme Empereur, Stiplastics Healthcaring’s Chairman-CEO. “Our decision to invest in Stiplastics Healthcaring is based on our assessment of the strength of the management team and our shared ambition on the company’s future. In particular, we have jointly identified the increased need for innovative solutions to improve observance and administration of medicines. We are delighted to be the new reference shareholder of this French company and to be given this opportunity to support its innovative strategy and international development plans.” says Jean-François Billet, Senior Partner at Mérieux Développement.

“Stiplastics Healthcaring has all the necessary assets to become a European market leader, including cutting-edge production facilities, excellent regulatory expertise and a deep understanding of its clients’ needs. We are very proud that Jérôme Empereur and the entire management team have chosen the Mérieux Développement-Gimv consortium to support them in their ambitious growth plans,” adds Benoit Chastaing, Partner Health & Care at Gimv.

The transaction is expected to close by the end of January 2018. No further financial details about this transaction will be disclosed.

Union Plastic presents its new innovative applicator cap APPLISIL® for vaginal cream

union-plastic

Union Plastic is specialized from the design to the manufacturing of medical device and pharmaceutical primary packaging.

Developed in partnership with laboratories and end-users for 6 months, the company launches during PHARMAPACK 2018 a new innovative applicator cap for its APPLISIL® range of product.

This new innovative cap improves traditional devices with its reinforced hygiene, security and ease of use.

 

 

The applicator cap APPLISIL® allows a 2 in 1 use: an adaptable side to the main vaginal cream tubes and a side suitable to the vaginal applicators APPLISIL® (dosage from 0.5 to 5 ml).
img1
This new product has a lot of advantages:

– Total absence of particle discharges (aluminum and/or plastic)
– Resealable stopper
– Adaptable to several aluminum tube diameters
– Reinforced hygiene
– Adaptable to the applicators APPLISIL®
– Tamper evident in option

The cap applicator APPLISIL® has got a patent registration and will be marketed from the second half-year 2018.

A bag full of novelties: Sanner at Pharmapack 2018

sanner

At Pharmapack Europe in Paris, visitors to booth C46-47 can see the whole range of desiccant solutions from Sanner, the manufacturer of high-quality primary plastic packaging and medical devices. In addition to integrated desiccants, Sanner presents its innovative drop-in solutions AdPack® and AdCap®. The AdPack® desiccant sachets made of Tyvek® material offer an ideal combination of breathability, moisture protection and durability. The desiccant capsules AdCap®, in turn, combine the advantages of conventional capsules and canisters, while offering high stability and a 30-percent higher moisture adsorption. Their unique grid structure enables 360-degree moisture adsorption and prevents mistakes during ingestion.

Tekni-Plex held successful grand opening at new China manufacturing facility

tekniplex

More than 40 government officials and 60 representatives from pharmaceutical and medical device companies attended the recent grand opening celebration for Tekni-Plex, Inc.’s new state-of-the-art manufacturing facility in Suzhou, China, near Shanghai. Plant tours and a luncheon followed the opening ceremony. Earlier this year, Tekni-Plex announced a $15 million investment in the facility to support the growing needs of the Asia-Pacific pharmaceutical and medical device markets that are supported with products developed by Tekni-Plex’s Colorite, Natvar and Action Technology business units.

Tekni-Plex senior management in attendance at the ribbon cutting included Paul Young, chief executive officer; Russell Hubbard, vice president-international and general manager; Ian Kenny, global managing director, Colorite; Johan Laureys, global vice president of Action Technology, and Bob Donohue, general manager of the company’s Natvar business unit. Xu Xiaofeng, standing committee member of CPC Wujiang Committee and deputy party secretary and vice chairman for Wujiang government, was also in attendance.

The more than 140,000-square-foot (13,000-square-meter) facility is manufacturing Tekni-Plex’s Natvar, Colorite and Action Technology products. The facility features three Class 100K cleanrooms to accommodate medical-grade tubing and components production plus one Class 10K cleanroom that will produce Natvar’s pharma-grade tubing.

The facility is in the process of commercializing Natvar’s recently-announced silicone extrusion tubing for catheters, feeding tubes, drug delivery and peristaltic pump applications. Production for microextrusion tubing that targets a wide variety of demanding neurovascular interventional therapies and surgical applications is expected to be on stream early next year. The facility will also manufacture Colorite custom compounds for medical device applications, and Action Technology’s dip tubes used in a wide variety of food/beverage, pharmaceutical, personal care, industrial and household pump applications.

Almac Group Announces Acquisition of BioClin Laboratories and Significantly Expands its Analytical Services

bioclin

Almac Group, the global contract development and manufacturing organisation, has announced the acquisition of BioClin Laboratories, an independent and privately owned organisation based in Athlone, Ireland.

Established in 2002 and located in Garrycastle, just two hours away from Almac Group’s Headquarters in Northern Ireland, BioClin is internationally recognised for providing expert analytical services including cGMP pharmaceutical and biopharmaceutical analysis, GMP microbiology testing and GLP bioanalysis. The company also boasts Ireland’s leading GLP certified (INAB), cGMP certified (HPRA) and FDA registered contract laboratory.

BioClin’s bespoke 14,000sq ft modern facility significantly increases Almac’s analytical capacity and perfectly complements its existing business enabling strategic expansion and greater ability to serve clients’ needs globally. The acquisition will see BioClin’s analytical experts join Almac Sciences’ strong network of almost 600 employees across multiple sites in Europe and North America.

Almac also recently completed significant expansion of its existing analytical facilities at its global headquarter site in Northern Ireland with the creation of a new, bespoke, MHRA approved laboratory.

News of this acquisition comes just days after announcing a multi-million pound expansion of Almac owned, Arran Chemical Company, also based in Athlone, which substantially increased Almac’s manufacturing capacity for fine chemicals, pharmaceutical intermediates and advanced building blocks.

“We are delighted to announce this acquisition demonstrating further commitment to strategic growth and development of our global business.” stated Dr Stephen Barr, Managing Director, Almac Sciences. “Adding BioClin’s highly complementary analytical capacity and technical expertise to our existing capabilities, we are able to broaden our service offerings and address our global clients’ growing demands for a high quality, integrated, efficient service. We look forward to working with the BioClin team and plan to invest significantly in this facility.”

Mary Burke, Managing Director, BioClin Laboratories commented “We are very pleased to join Almac. With our shared values for outstanding quality, expertise and innovation we see this as an excellent strategic fit for BioClin enabling us to expand and deliver an enhanced range of analytical solutions to an international client market.”

AptarGroup wins Sustainability Initiative of the Year at CPhI Pharma Awards

actu-03

AptarGroup announced that it was awarded the inaugural Excellence in Pharma: Sustainability Initiative of the Year at CPhI Worldwide 2017. The award was presented as part of the CPhI Pharma Awards Gala, which took place Tuesday, October 24 at the Intercontinental Hotel in Frankfurt, Germany.

Established in 2004, the CPhI Pharma Awards are one of the most prestigious recognitions in the Pharmaceutical industry today. This year’s awards included eight new categories to further reflect the industry’s diversity. The Sustainability Initiative of the Year is one of this year’s new categories. There were over 200 entries across the 19 award categories, and finalists for the awards were announced in August 2017.

Aptar was awarded the Excellence in Pharma: Sustainability Award for its Landfill Free Certification program, a global internal certification program which promotes the efficiencies and conservation of natural resources in a manufacturing setting. Facilities that achieve at least a 90 percent reuse and/or recycling threshold are eligible to receive internal Landfill Free Certification. With more than 40% of Aptar’s manufacturing sites already certified through this program, Aptar has achieved significant accomplishments in waste reduction, cost savings and employee engagement. The program is incorporated as a measurable aspect of Aptar‘s global sustainability strategy and Aptar anticipates more facilities will achieve certification in years to come.

Data from Aptar’s recent customer satisfaction surveys demonstrated the growing importance of sustainability to customers and supply partners. Therefore, Aptar’s internal program further reinforces that Aptar is prioritizing the needs of its customers in line with its own company mission and corporate social responsibility.

Yann Ghafourzadeh, VP, Sales & Operations Europe – Prescription Division, commented, “We are delighted to have been awarded the Sustainability Initiative of the Year at the CPhI Pharma Awards. It is great to be recognised for the progression of Aptar’s Landfill Free Certification program, which has been significant within our global sustainability strategy. We have aligned our program with our customers’ requirements and we are dedicated to responding to what sustainability considerations are important to them. We look forward to further Aptar facilities obtaining the internal Landfill Free Certification in the future.”

ARaymondlife continues to develop and commercialize its RayDyLyo® range collaborating with Dara Pharmaceutical Packaging.

Logos_fabrication

 

 

 

• RayDyLyo®, an innovative device for vial capping

ARaymondlife is a pharmaceutical company GMP EU, specialized in plastic injection molding and fastening solutions. Its technological expertise is applied to develop innovative solutions for the pharmaceutical laboratories (for human health and veterinary medicine) and the medical industry.
Since 2012 ARaymondlife has been offering its own range of patented all plastic caps as an alternative to aluminum crimped closures. RayDyLyo® is more than a product; it is a solution that simplifies and improves the process security of the vial capping operation. Several packaging options are available in bulk or in nests to meet the market’s diverse needs. The trend toward ready-to-use components and filling vials directly in nests makes RayDyLyo® a very well-adapted solution.
RayDyLyo® eliminates the need for crimping by pre-assembling the stopper in the cap and closing the vial by simple vertical pressure, either automatically or manually.

• The first filling line adapted for RayDyLyo®

ligne DARA_AR - copieDara Pharmaceutical Packaging was showing the first vial filling line specially adjusted for filling and capping vials with RayDyLyo® at the CPhl in Frankfurt (24-26 October 2017).The Spanish company responded to ARaymondlife’s request to develop a suitable machine for feeding the all-in-one solution (a stopper pre-assembled in the plastic closure) and the specific parts needed to adapt the line.
Pre-assembling the stopper upstream simplifies the process compared to a traditional line by eliminating thestopper placing and crimping operations and saves space in the clean room.

« We believe that this first filling line will be introduced to the market progressively, but we are convinced that this product will gain significant market share in the medium term. DARA new vials filling lines, are ready to implement this new technology. Also and this is the most important thing, DARA old machinery, due to its modularity construction, allows an easy, economical and fast retrofit, to combine this new RayDyLyo® system with the traditional stopper and alu cap technology. RayDyLyo® is a highquality product that fits perfectly with Dara’s filling lines. » Joan Melé, Dara Pharmaceutical Packaging Commercial Director.

For its development, ARaymondlife has already concluded other partnerships, in particular with the “Matrix Alliance”, on the initiative of Vanrx Pharmasystems, allowing to propose an aseptic filling solution in a fully robotized isolator, or more recently with Disposable-Lab Eurofins Amatsigroup to offer to biotechs and pharmaceutical companies a global solution for the aseptic filling of innovative biological products.
“We want to continue to develop industrial partnerships such as the one with Dara Pharmaceutical Packaging because we are convinced that we are stronger together and that the answers we bring to the market are more relevant,” explains Nicolas Thivant, President of ARaymondlife.

• Innovation and diversity are part of ARaymond’s DNA

Discovering new markets where its know-how and its potential for innovation make sense has been the driving force behind ARaymond’s development for more than 150 years. As one of the world leaders in fastening and assembly solutions for the automotive industry, it has gradually transferred its skills and expertise to new markets: Truck, Industrial, Energies, Agriculture and Life.
« We believe in ARaymondlife’s potential because it is an ambitious project driven by the passion and involvement of the people who lead it and it respects the values of our company. We are convinced that our employees’ enthusiasm and motivation will make a difference over the long term, » says François Raymond, General Director of the ARaymond Network. For the company, diversification also means ensuring its stability and independence despite the political and economic uncertainties that may affect a sector or a country.